Current and future use of dipyridamole in patients with COVID-19
Current use of dipyridamole in COVID-19 is mainly based on its antithrombotic activity, since there is no robust clinical effectiveness data. The decision to use dipyridamole in COVID-19 should be individualized, considering the experimental nature of this treatment.
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Russo |
| Publicat: |
Izdatelstvo OKI
2020-10-01
|
| Col·lecció: | Качественная клиническая практика |
| Matèries: | |
| Accés en línia: | https://www.clinvest.ru/jour/article/view/536 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|